☣️ "It was poison..."

Here are three valuable lessons I learned about investing in biotech companies... [Shield] AN OXFORD CLUB PUBLICATION [Wealthy Retirement]( [View in browser]( SPONSORED America no longer a superpower because of Biden? [White House]( [Ever heard of America's "Doomsday Deal"?]( It's a deal so vital to our country's wealth and security... Every President for 50 years has defended it at all costs. Until Calamity Joe Biden. Biden broke the deal. And I now predict... The America we love is doomed. And the biggest wealth transfer in U.S. history is now underway. [>>See the truth about Biden's terrible mistake HERE<<]( BREAKING NEWS: [The #1 weight loss drug is set to hit the market.]( And no, it's NOT Ozempic... or likely anything you've heard of. The Wall Street Journal reports that "[the King Kong of weight loss drugs is coming]( And Chief Income Strategist Marc Lichtenfeld sees [one BIG catalyst approaching quickly](. That's why you must watch his urgent message BEFORE September 6. This opportunity is so huge that [Marc is giving away the ticker symbol of the company behind it for FREE](. [Discover what could be the biggest medical breakthrough of our lifetime here.]( - Rachel Gearhart, Associate Publisher [MARKET TRENDS]( [Three Lessons From the Drug That Wasn't Water]( [Marc Lichtenfeld, Chief Income Strategist, The Oxford Club]( [Marc Lichtenfeld]( "It's either water, or it's not water. And we know it's not water." That's what the CEO of a small cap biotech company said to me in a hotel suite during the J.P. Morgan Healthcare Conference. He was talking about his company's groundbreaking cancer drug that was in clinical trials. He was basically telling me that the drug worked. The CEO was a Harvard grad, and he was energetic and charismatic. I believed him. I was early in my career covering biotech stocks, and this drug tackled a difficult-to-treat cancer. I wanted the medicine to work for patients, and I wanted the recommendation to work for my readers, as we were getting in early. My readers made a tiny bit on the stock, but not a ton, as we got stopped out when the stock started to slip after an initial gain. I was disappointed to get stopped out, but I stuck to my discipline and recommended selling the stock when the stop was hit. Boy, am I glad I did. It turns out that the CEO was right. The drug wasn't water. It was poison. Not only did the Phase 2 data show that the drug did nothing to treat cancer, but patients on the therapy had a higher death rate than those not taking it. You can imagine what happened next. The stock fell faster than sales of Bud Light. It dropped from about $15 to below $1 and eventually became a zero. As I said, this was very early in my days covering biotech, about 15 years ago. I learned three valuable lessons... Lesson No. 1: Fine-tune your BS detector. CEOs of publicly traded companies are typically measured in what they say about their companies or, in the case of biotech and pharmaceutical companies, what they say about their drugs. They'll tell you what the data shows and will of course be bullish, but they won't say definitively that a drug is safe and effective until the Food and Drug Administration says it is. The guy I talked to was so cocky about his drug, alarm bells should have been ringing. If you ever hear a biotech CEO talking exuberantly and definitively about a drug that has not finished clinical trials yet, be wary. SPONSORED [PROOF: New One Ticker (Weekly) Payouts]( [Calendar; January - June]( A multimillionaire stock trader's research explains how focusing on just one ticker every week has generated payouts up to a rare 2,614% in under 11 days... AND he's brought proof to show the world! [SEE THE PROOF]( Lesson No. 2: Look at the data. When it comes to clinical trials, understand what the data shows. A drug may have shown effectiveness in an early trial, but if the number of participants was low or if the study wasn't double-blind (where patients and doctors don't know who is getting the drug), the data may not be accurate. That doesn't mean the drug doesn't work. Many successful blockbusters started with a small trial. But you should temper your expectations until a larger, more rigorous trial is conducted. Because lots of failed drugs started with a small trial too. Lesson No. 3: Stick to your stops. I've always been disciplined when it comes to trading. When a stop is hit, no matter how bullish I am, I sell. I may look for a better opportunity to buy it later, but a stop is placed when you enter a trade, at a time when emotions are not heightened. It's too easy to make excuses and justify why you should stay in a trade when you're upset about getting stopped out. Stops take the emotion out of trading, and that's the single most important thing you can do to improve your results. Honor your stops. The Cost of Learning Everyone makes mistakes and pays "tuition" - the cost of learning - when they start trading. I certainly have. Luckily, this one wasn't costly at the time. But the lessons I learned helped shape the way I invest and trade - especially in the biotech and pharma sectors. And the next time you hear a CEO talking about their company, ask yourself whether the statement is equivalent to the "It's not water" declaration. If it is, run - don't walk - away. Good investing, Marc P.S. I've recently spotted an opportunity in the healthcare sector that I'm really excited about. And I expect [a major catalyst to boost the stock SOON](. [Here's what you need to know to position yourself for a potential windfall.]( [Leave a Comment]( [Investment U Conference 2024 at the Ojai Valley Inn & Spa in Ojai, California. Don't miss out!]( RECOMMENDED LINKS [The Man Who Called the Market Bottoms in '02, '09 and '20 Makes Shocking Prediction. Click Here to Find Out What It Is.]( [One Potentially Explosive Stock That Alexander Green Just Discovered Has Seen Five-Year 2,000% Revenue Growth, Enjoys 70% Gross Margins and Sports a Debt-Free Balance Sheet, yet Still Trades Under $10. He's Calling It the "Next Great American Super Stock." (Click for Details.)]( MORE FROM WEALTHY RETIREMENT [Image of medical technology]( [How to Invest in the Healthcare Sector]( [Image of the Fleetcor Technologies logo]( [Fleetcor Technologies: Should You Invest?]( [Image of Healthpeak Properties]( [PEAK Stock: How Healthy Is This 5.9% Yield?]( [Image of 401(k) plan written on a sticky note]( [How to Determine How Much to Contribute to Retirement]( [Facebook]( [Facebook]( [Twitter]( [Twitter]( [Email Share](mailto:?subject=A%20great%20piece%20from%20Wealthy%20Retirement...&body=From%20Wealthy%20Retirement:%0D%0A%0D%0AHere are three valuable lessons I learned about investing in biotech companies...%0D%0A%0D [Email Share](mailto:?subject=A%20great%20piece%20from%20Wealthy%20Retirement...&body=From%20Wealthy%20Retirement:%0D%0A%0D%0AHere are three valuable lessons I learned about investing in biotech companies...%0D%0A%0D [Push Alert]( [Push Alert]( SPONSORED [Bad News - Good News]( One $8 Stock Could Help Put You on the Right Side of This Equation. [Click Here for Details]( [The Oxford Club]( You are receiving this email because you subscribed to Wealthy Retirement. Wealthy Retirement is published by The Oxford Club. Questions? Check out our [FAQs](. Trying to reach us? [Contact us here.]( Please do not reply to this email as it goes to an unmonitored inbox. [Privacy Policy]( | [Whitelist Wealthy Retirement]( | [Unsubscribe]( © 2023 The Oxford Club, LLC All Rights Reserved The Oxford Club | [105 West Monument Street](#) | [Baltimore, MD 21201](#) North America: [877.808.9795](#) | International: [+1.443.353.4621](#) [Oxfordclub.com]( Nothing published by The Oxford Club should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The Oxford Club, LLC, 105 West Monument Street, Baltimore, MD 21201.